Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 7,709 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 7,709 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $32.75, for a total transaction of $252,469.75. Following the sale, the insider directly owned 61,804 shares of the company’s stock, valued at $2,024,081. The trade was a 11.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $33.27, for a total transaction of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30.

Mineralys Therapeutics Trading Down 6.1%

Mineralys Therapeutics stock opened at $31.38 on Friday. Mineralys Therapeutics, Inc. has a 12-month low of $8.24 and a 12-month high of $47.65. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -10.64 and a beta of 0.49. The firm has a 50 day moving average of $38.51 and a 200 day moving average of $30.91.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. On average, analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MLYS. Stifel Nicolaus lifted their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wells Fargo & Company upped their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright upped their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Mineralys Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock worth $124,000 after purchasing an additional 3,241 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Mineralys Therapeutics by 42.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after acquiring an additional 1,197 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in Mineralys Therapeutics in the third quarter worth approximately $216,000. Institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.